☆ 4.6 Meeting Abstract

The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

JOURNAL OF THORACIC ONCOLOGY (2019)

Journal

JOURNAL OF THORACIC ONCOLOGY

Volume 14, Issue 10, Pages S625-S626

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jtho.2019.08.1318

Keywords

Chemotherapy; durvalumab; NSCLC

Categories

Oncology Respiratory System

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC

Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, Yiduo Zhang

Summary: Durvalumab was found to be cost-effective compared with cCRT alone in patients with unresectable stage III NSCLC in a US healthcare setting, with incremental cost-effectiveness ratios indicating it was below the willingness-to-pay threshold. Sensitivity and scenario analyses highlighted variables affecting the model, but overall the adoption of Durvalumab following cCRT as the new standard of care was supported.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)

Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey Daniel, Augusto Villegas, David Vicente, Rina Hui, Shuji Murakami, Luis Paz-Ares, Helen Broadhurst, Catherine Wadsworth, Phillip A. Dennis, Scott J. Antonia

Summary: The PACIFIC trial showed that durvalumab improves PFS and OS in Stage III NSCLC patients, regardless of their response to prior CRT. However, in some subgroups, such as patients who received induction chemotherapy, the impact of durvalumab on OS may be limited.

LUNG CANCER (2021)

Add to Collection

Article Oncology

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

Jacqueline V. Aredo, Isa Mambetsariev, Jessica A. Hellyer, Arya Amini, Joel W. Neal, Sukhmani K. Padda, Caroline E. McCoach, Jonathan W. Riess, Elwyn C. Cabebe, Jarushka Naidoo, Tariq Abuali, Ravi Salgia, Billy W. Loo Jr, Maximilian Diehn, Summer S. Han, Heather A. Wakelee

Summary: Consolidation durvalumab did not benefit patients with EGFR-mutated unresectable stage III NSCLC and was associated with a high frequency of immune related adverse events. Patients who switched to osimertinib after durvalumab treatment may be more susceptible to incident adverse events. Further investigation is needed for concurrent CRT with induction or consolidation EGFR TKIs as definitive treatment.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest

Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

Myung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, Byoung Chul Cho, Shunichi Sugawara, Gabriella Galffy, Byoung Yong Shim, Nikolay Kislov, Rajnish Nagarkar, Ingel Demedts, Steven J. M. Gans, Dolores Mendoza Oliva, Ross Stewart, Zhongwu Lai, Helen Mann, Xiaojin Shi, Maen Hussein

Summary: The ORION study evaluated the effectiveness of olaparib in combination with durvalumab as maintenance therapy for patients with metastatic NSCLC. The results showed that the combination therapy did not significantly improve progression-free survival compared to durvalumab alone, although there was a numerical improvement.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

Paolo Borghetti, Jessica Imbrescia, Giulia Volpi, Vieri Scotti, Michele Aquilano, Alessio Bruni, Davide Franceschini, Stefano Ursino, Patrizia Ciammella, Gaia Piperno, Maria Taraborrelli, Stefano Maria Magrini

Summary: This article describes the pattern of relapse, progression-free survival (PFS), and overall survival (OS) in patients treated with radio-chemotherapy and durvalumab for loco-regional relapse after surgical resection of non-small-cell lung cancer (NSCLC). The results suggest that this treatment strategy may prolong post recurrence survival in patients with good performance status experiencing loco-regional relapse after surgery.

RADIATION ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

Joao V. V. Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J. J. Rodig, Emily S. S. Lebow, Jordan E. E. Eicholz, Maria Thor, Andreas Rimner, Adam J. J. Schoenfeld, Jamie E. E. Chaft, Bruce E. E. Johnson, Daniel R. R. Gomez, Mark M. M. Awad, Narek Shaverdian

Summary: Concurrent chemoradiation and durvalumab is the standard of care for stage III non-small cell lung cancer, but its efficacy varies. The authors found that PD-L1 tumor proportion score expression and increased tumor mutational burden can predict response, and early-onset pneumonitis leading to durvalumab discontinuation is associated with poor survival.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC

Christian Wilhelm Langberg, Henrik Horndalsveen, Aslaug Helland, Vilde Drageset Haakensen

Summary: This study identifies factors associated with failure to start consolidation immunotherapy after chemoradiotherapy in patients with non-small cell lung cancer. Results show that patients with higher lactate dehydrogenase, worse performance status, cumulative toxicity, and higher c-reactive protein are less likely to start immunotherapy. Further research and prospective trials are needed to investigate the potential of prehabilitation and supportive treatment in optimizing treatment outcomes.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Updated Prognostic Factors in Localized NSCLC

Simon Garinet, Pascal Wang, Audrey Mansuet-Lupo, Ludovic Fournel, Marie Wislez, Helene Blons

Summary: This review discusses the need for improved risk assessment and patient selection for adjuvant and neoadjuvant chemotherapy following resected lung cancer. The current evaluation of recurrence risk is primarily based on TNM classification, but more than 25% of early-stage patients still experience relapse. Validated prognostic and theranostic markers are needed to better stratify patients and guide adjuvant therapies in resected lung cancer.

CANCERS (2022)

Add to Collection

Article Oncology

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Francesco Cortiula, Dirk De Ruysscher, Michelle Steens, Robin Wijsman, Anthonie van der Wekken, Martina Alberti, Lizza E. L. Hendriks

Summary: Adjuvant durvalumab is the standard treatment for stage III unresectable non-small cell lung cancer (NSCLC) patients without progression after chemo-radiation. Patients with EGFR mutations and ALK rearrangements do not benefit from durvalumab. This retrospective study showed that patients with uncommon driver genomic alterations (dGA), including KRAS mutations, had a meaningful survival benefit from adjuvant durvalumab.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro Jr, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martin, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vynnychenko, Sung Yong Lee, Maciej Bryl, Alona Zer, Mustafa Erman, Constanta Timcheva, Rajiv Raja, Kirsha Naicker, Urban Scheuring, Jill Walker, Helen Mann, Vikram Chand, Tony Mok

Summary: In the NEPTUNE study, first-line durvalumab plus tremelimumab did not show significant improvement in overall survival compared to chemotherapy in patients with metastatic NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Article Oncology

Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

Marina C. Garassino, Julien Mazieres, Martin Reck, Christos Chouaid, Helge Bischoff, Niels Reinmuth, Laura Cove-Smith, Talal Mansy, Diego Cortinovis, Maria R. Migliorino, Angelo Delmonte, Jose Garcia Sanchez, Luis Enrique Chara Velarde, Reyes Bernabe, Luis Paz-Ares, Ignacio Diaz Perez, Nataliya Trunova, Kayhan Foroutanpour, Corinne Faivre-Finn

Summary: The study included 117 patients with advanced unresectable stage III NSCLC, showing that durvalumab after sequential CRT has a comparable safety profile to durvalumab after concurrent CRT and has promising preliminary efficacy in a frailer population.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Jessica A. Hellyer, Jacqueline Aredo, Millie Das, Kavitha Ramchandran, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee

Summary: This retrospective analysis of patients with unresectable stage III NSCLC treated with consolidation durvalumab identified a shorter disease-free survival in patients with ERBB2/EGFR mutations. Further prospective studies are needed to evaluate this finding in the future.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano

Summary: Single immune checkpoint blockade has limited efficacy in patients with NENs. However, dual checkpoint blockade with durvalumab and tremelimumab shows promising results in patients with advanced NENs of gastroenteropancreatic and lung origin. This study highlights the potential of durvalumab plus tremelimumab as a treatment option for NENs patients.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez, Julien Mazieres, Armelle Lavole, Gerard Zalcman, Olivier Carre, Thomas Egenod, Raffaele Caliandro, Catherine Dubos-Arvis, Gaelle Jeannin, Olivier Molinier, Marie-Ange Massiani, Alexandra Langlais, Franck Morin, Francoise Le Pimpec Barthes, Laurent Brouchet, Jalal Assouad, Bernard Milleron, Diane Damotte, Martine Antoine, Virginie Westeel

Summary: This study assessed the feasibility of neoadjuvant durvalumab for early-stage resectable non-small-cell lung cancer. The results showed that this treatment approach resulted in a high complete resection rate and some pathological response. However, the unexpectedly high postoperative mortality rate led to the premature termination of the study.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Editorial Material Oncology

Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?

Lizza E. L. Hendriks, Jessica Menis, Dirk K. M. De Ruysscher, Martin Reck

JOURNAL OF THORACIC ONCOLOGY (2020)

Add to Collection

Article Oncology

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Santiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, Manuel Cobo Dols, Pieter E. Postmus, Conrad Lewanski, Jaafar Bennouna, Juergen R. Fischer, Oscar Juan-Vidal, David J. Stewart, Andrea Ardizzoni, Rafia Bhore, Marianne Wolfsteiner, Martin Reck, Teng Jin Ong, Daniel Morgensztern

FUTURE ONCOLOGY (2020)

Add to Collection

Article Oncology

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Shirish Gadgeel, Delvys Rodriguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Domine, Rina Hui, Maximilian J. Hochmair, Philip Clingan, Steven F. Powell, Susanna Yee-Shan Cheng, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Edward B. Garon, Silvia Novello, Belen Rubio-Viqueira, Michael Boyer, Takayasu Kurata, Jhanelle E. Gray, Jing Yang, Tuba Bas, M. Catherine Pietanza, Marina C. Garassino

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial

S. Peters, J-L. Pujol, U. Dafni, M. Domine, A. Becker, J. Andrade, A. Curioni-Fontecedro, O. Molinier, D. Moro-Sibilot, K. Nackaerts, A. Insa Molla, G. Lopez Vivanco, J. Madelaine, S. Popat, M. Reck, H. Roschitzki-Voser, P. Mitchell, D. De Ruysscher, C. Le Pechoux, R. Stahel

ANNALS OF ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

M. Reck, T-E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, Y. Cheng, L. Paz-Ares, S. Lu, T. John, B. Padilla, X. Sun, A. Moisei, J. Yan, Y. Yuan, S. I. Blum, D. P. Carbone

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Oncology

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA

Jordi Remon, Benjamin Lacas, Roy Herbst, Martin Reck, Edward B. Garon, Giorgio V. Scagliotti, Rodryg Ramlau, Nasser Hanna, Johan Vansteenkiste, Kiyotaka Yoh, Harry J. M. Groen, John V. Heymach, Sumithra J. Mandrekar, Isamu Okamoto, Joel W. Neal, Rebecca S. Heist, David Planchard, Jean-Pierre Pignon, Benjamin Besse

Summary: This study validates the efficacy of combining angiogenesis inhibitors with second-line treatment in advanced non-small cell lung cancer (NSCLC) patients, showing significant improvements in overall survival and progression-free survival, particularly in younger patients and those who started the first-line therapy more recently.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal, Aurelia Alexandru, Ying Cheng, Hiroshi Sakai, Luis Paz-Ares, Shun Lu, Thomas John, Xiaowu Sun, Aniela Moisei, Fiona Taylor, Rachael Lawrance, Xiaoqing Zhang, Judi Sylvester, Yong Yuan, Steven I. Blum, John R. Penrod, David P. Carbone

Summary: In the CheckMate 9LA study, first-line nivolumab plus ipilimumab with chemotherapy significantly improved overall survival compared to chemotherapy alone in patients with metastatic non-small cell lung cancer and no known sensitising epidermal growth factor receptor/anaplastic lymphoma kinase alterations. We presented exploratory patient-reported outcomes (PROs) with a minimum follow-up of 2 years.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Review Oncology

TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC

Benjamin P. Levy, Enriqueta Felip, Martin Reck, James C. H. Yang, Federico Cappuzzo, Yasuto Yoneshima, Caicun Zhou, Siddhartha Rawat, Jingdong Xie, Priyanka Basak, Lu Xu, Jacob Sands

Summary: The TROPION-Lung08 study is a Phase III trial evaluating the safety and efficacy of Dato-DXd plus pembrolizumab versus pembrolizumab monotherapy for advanced/metastatic NSCLC patients without AGAs and with PD-L1 tumor proportion score =50%. The primary endpoints are progression-free survival and overall survival, while secondary endpoints include objective response rate, duration of response, safety, and presence of antidrug antibodies.

FUTURE ONCOLOGY (2023)

Add to Collection

Article Oncology

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, Reyes Bernabe Caro, Helena Linardou, Jacobus A. Burgers, Makoto Nishio, Alex Martinez-Marti, Koichi Azuma, Rita Axelrod, Luis G. Paz-Ares, Suresh S. Ramalingam, Hossein Borghaei, Kenneth J. O'Byrne, Li Li, Judith Bushong, Ravi G. Gupta, Diederik J. Grootendorst, Laura J. Eccles, Julie R. Brahmer

Summary: The combination therapy of nivolumab and ipilimumab has shown prolonged overall survival in patients with metastatic NSCLC, regardless of tumor PD-L1 expression. The study also demonstrated that this combination therapy remains effective in patients with baseline brain metastases and has better intracranial efficacy compared to chemotherapy.

JOURNAL OF THORACIC ONCOLOGY (2023)

Add to Collection

Review Oncology

Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives

Martin Reck, Sanjay Popat, Christian Grohe, Jesus Corral, Silvia Novello, Maya Gottfried, Wolfgang Brueckl, Dejan Radonjic, Rolf Kaiser, John Heymach

Summary: The use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced non-small cell lung cancer (NSCLC) has been a major breakthrough. However, there is a need for effective second-line treatment options, prompting research into the combination of anti-angiogenic agents with immunotherapy. Ongoing clinical trials are evaluating the efficacy of these combinations.

LUNG CANCER (2023)

Add to Collection

Review Oncology

Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges

Giannis Mountzios, Jordi Remon, Lizza E. L. Hendriks, Rosario Garcia-Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters

Summary: Several trials are being conducted to test immune-checkpoint inhibitors (ICIs) in patients with resectable non-small-cell lung cancer as adjuvant, neoadjuvant or perioperative approaches. However, the efficacy of ICIs with curative intent in early stage non-small-cell lung cancer remains unclear. This review discusses the current trial landscape, challenges, and opportunities.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Nivolumab (NIVO) plus ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

M. Thomas, S. S. Ramalingam, T. E. Ciuleanu, A. Pluzanski, J. -S. Lee, M. Schenker, R. Bernabe Caro, K. H. Lee, B. Zurawski, C. Audigier-Valette, M. Provencio, H. Linardou, S. -W. Kim, H. Borghaei, M. D. Hellmann, K. J. O'Byrne, L. G. Paz-Ares, M. Reck, F. E. Nathan, J. R. Brahmer

ONCOLOGY RESEARCH AND TREATMENT (2020)

Add to Collection

Meeting Abstract Oncology

Efficacy of afatinib in the clinical practice - final results of the GIDEON study in EGFR mutated NSCLC in Germany

J. Rawluk, E. Laack, M. Reck, H. Schaefer, C. Kortsik, T. Gaska, S. Krueger, K. Kokowski, S. Budweiser, J. H. Ficker, C. Hoffmann, A. Schueler, W. M. Brueckl

ONCOLOGY RESEARCH AND TREATMENT (2020)

Add to Collection

Article Oncology

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

Edward B. Garon, Giorgio Vittorio Scagliotti, Oliver Gautschi, Martin Reck, Michael Thomas, Lara Iglesias Docampo, Haralabos Kalofonos, Joo-Hang Kim, Steven Gans, Odd Terje Brustugun, Sergey V. Orlov, Gebra Cuyun Carter, Annamaria H. Zimmermann, Ana B. Oton, Ekaterine Alexandris, Pablo Lee, Katharina Wolff, Victoria Jennifer Stefaniak, Mark A. Socinski, Maurice Perol

ESMO OPEN (2020)

Add to Collection

Article Respiratory System

NELSON Study: CT Screening reduces Lung Cancer Mortality

Iris Watermann, Martin Reck

PNEUMOLOGE (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.